MOUNTAIN VIEW, Calif., Nov. 29, 2016 /PRNewswire/ -- Cellecta, Inc. today announced the launch of Driver-Map™ Human Genome-Wide Expression Profiling Service, a targeted RNA expression method that allows quantitative expression analysis of all known 19,000 protein-coding genes in the human genome from as little as 10 pg of total RNA.
The multiplex RT-PCR-based-, followed by next-generation sequencing (NGS), method applied in the Driver-Map Expression Profiling Service addresses the limitations in specificity, reproducibility and sensitivity of other genome-wide expression profiling approaches such as RNA-Seq and microarray platforms.
"The advanced methods now available to researchers through the Driver-Map Genome-Wide service will enable expression profiling of even the most complex samples such as those from xenografts, whole blood and tissue biopsies. We look forward to enabling a more efficient path to discovery of novel diagnostics and therapeutic agents for a wide variety of disease areas," said Alex Chenchik, Ph.D., founder and CEO of Cellecta.
The highly reproducible Driver-Map™ assay employs a robust, single-test-tube protocol which features unique improvements that are particularly suitable to complex applications such as large-scale biomarker discovery, tumor microenvironment characterization, and others which require minimal amounts of RNA sample. These improvements include:
- Selective amplification targets 19,000 annotated human transcripts using RT-PCR directly from total RNA--requiring no previous rRNA purification, globin depletion or polyA enrichment steps. This results in less complex, more reproducible protocols; a streamlined workflow, simplified data analysis and greater sensitivity.
- Functionally validated and individually selected PCR primers comprise an optimal genome-wide primer set that reliably measure mRNAs. This optimal primer set allows for a more comprehensive view of the spectrum of gene regulation, and detection of low- as well as highly abundant transcripts. The resulting 1,000 to 10,000-fold dynamic range represents 100-fold greater sensitivity than RNA-Seq or microarrays.
- Built-in, internal controls of synthetic RNAs compensate for batch effects and routine day-to-day variation, resulting in greater RNA quality control.
The basic service includes extensive sample RNA quality control, the Driver-Map™ assay, next-generation sequencing to determine the relative number of transcripts of each gene, and comprehensive analysis— resulting in multiplex data that is annotated, normalized, with basic statistical analysis presented in the final report.
Driver-Map™ Human Genome-Wide Expression Profiling Service is available now. For more information, please visit www.driver-map.com
Cellecta, Inc., a leading provider of genomic products and services, is an industry leader in RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets, and genetic profiling for biomarker discovery. Numerous scientific papers have been published citing Cellecta's functional genomics portfolio offering gene knockout and knockdown screens, custom and genome-wide RNAi and CRISPR libraries, cell engineering, RNAi and CRISPR construct services, and mutation and expression profiling of disease samples.
Cellecta, Inc. is headquartered in Mountain View, California. Further information about the company and its functional genomic products and services may be found online at www.cellecta.com
Paul Diehl, 650-938-4050
Ruth Mercado, 650-938-4080
SOURCE Cellecta, Inc.